14 September 2020This recent retrospective study analysed the histology, management and outcomes of renal immune adverse events in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy. It found renal immune-related adverse events are most commonly attributable to steroid responsive acute tubulointerstitial nephritis.
13 September 2020This report summarises the latest findings in melanoma research, including insights into the tumor microenvironment and new biomarkers, improved understanding of tumor immune response and resistance, novel approaches for combination strategies and the role of neoadjuvant and adjuvant therapy which were discussed at the Melanoma Bridge meeting held on 5–7 December, 2019, Naples, Italy.
11 September 2020The Australian Government is expanding the Pharmaceutical Benefits Scheme (PBS) listing of pembrolizumab for adjuvant treatment of melanoma.
11 September 2020Richard McKenzie, an emeritus scientist with the National Institute of Water and Atmospheric Research (NIWA) at Lauder has recently released a new book titled "Saving Our Skins: Atmospheric Reflections of a Lauder Stargazer."
8 September 2020This recent study reviewed smartphone mobile applications for skin cancer detection in relation to availability, functionality, and costs to users over time. Results showed a steady increase in the number of apps available to support prevention or early detection of skin cancers, however many still appear to lack clinician input and evidence for their safety and value.
8 September 2020The five year follow-up of this recent phase 3 trial involving patients who had resected stage III melanoma with BRAF V600E or V600K mutations showed 12 months of adjuvant therapy with dabrafenib plus trametinib resulted in a longer duration of survival without relapse or distant metastasis than placebo with no apparent long-term toxic effects.
3 September 2020This recent study developed a new prognostic 21-gene signature for cutaneous melanoma patients. According to the results, high risk patients demonstrated carcinogen metabolism enrichment and immune inhibition when compared to those categorised as low risk.
3 September 2020This recent New Zealand study analysed morphological evolution in melanoma in situ using revised pattern analysis. It concluded that lesions predominantly increased in morphological complexity over time. This supports longer follow up periods to allow dermoscopic features associated with malignancy and histopathological progression to develop.
1 September 2020This recent study proposes consensus definitions for retreatment and rechallenge in relation to patients with BRAF-mutant melanoma who have developed resistance to BRAF inhibitor and MEK inhibitor treatment.
29 August 2020According to this recent study, melanoma brain metastases have a unique molecular profile when compared with primary cutaneous melanoma and extracranial metastases, including higher rates of BRAF mutations, higher tumour mutational burden and higher PD-L1 expression.
